The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
The impact of post-remission G-CSF on outcomes in the VIALE-A and VIALE-C trials
|
A post hoc analysis assessed the impact of post-remission G-CSF in patients with ND AML who were ineligible for intensive chemotherapy and received venetoclax + azacitidine or venetoclax + LDAC in the phase III VIALE-A (NCT02993523) and VIALE-C (NCT03069352) trials, respectively.1 Results were published in the American Journal of Hematology by DiNardo et al.1 |
| Key learnings |
| The median DOR was 25.5 months and 15.3 months in patients who received G-CSF vs 12.8 months and 11.5 months in those who received no G-CSF in the VIALE-A and VIALE-C trials, respectively. |
| The median OS was 30.8 months and 23.0 months in patients who received G-CSF vs 21.1 months and 13.7 months in those who received no G-CSF in the VIALE-A and VIALE-C trials, respectively. |
| Patients who received G-CSF post-remission with venetoclax-based treatment in the VIALE-A and VIALE-C trials had shorter delays between treatment cycles vs patients who did not receive G-CSF, with no new safety signals. |
| Results suggest that incorporating G-CSF to the recommended dose modifications of venetoclax does not negatively impact OS or DOR, is well tolerated, and reduces delays between treatment cycles, potentially contributing to improved outcomes in patients with ND AML. |
Abbreviations: AML, acute myeloid leukemia; DOR, duration of response; G-CSF, granulocyte-colony stimulating factor; LDAC, low-dose cytarabine; ND, newly diagnosed; OS, overall survival.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?
